title: [Clinical analysis of 12 cases of uterine carcinosarcoma].
abstract: OBJECTIVE
  Uterine carcinosarcoma, also known as malignant mixed mullerian tumors, is an uncommon neoplasm that carries a poor prognosis. This study was to analyze the clinical manifestation, diagnosis, treatment and prognosis of this disease.
  
  
  METHODS
  Clinical data of 12 uterine carcinosarcoma patients, diagnosed in Cancer Center of Sun Yat-sen University from 1978 to 2004, were analyzed.
  
  
  RESULTS
  Of the 12 cases of uterine carcinosarcoma, 2 were in the cervix, 10 in the corpus uteri. The main clinical manifestation of cervical carcinosarcoma was contact vaginal bleeding. Carcinosarcoma in the corpus uteri manifested abnormal vaginal bleeding and postmenstrual bleeding. Diagnosis depended on pathology. Twelve patients undergone operation. Eight patients received chemotherapy and 2 received radiotherapy after operation. One cervical carcinosarcoma patient died within 2 year. The 1-, 3-, and 5-year survival rates of the 12 patients were 80.0%, 50.0%, and 50.0%,respectively.
  
  
  CONCLUSIONS
  Primary surgery is the main treatment for uterine carcinosarcoma. The prognosis of uterine carcinosarcoma is associated with surgicopathologic stage and treatment modalities.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.
authors.forename: Luan-Hong
authors.initials: LH
authors.lastname: Wang
authors.forename: Ying
authors.initials: Y
authors.lastname: Xiong
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Li
authors.forename: Jun-Dong
authors.initials: JD
authors.lastname: Li
authors.forename: Yan-Ling
authors.initials: YL
authors.lastname: Feng
authors.forename: Yu-Jie
authors.initials: YJ
authors.lastname: Li
authors.forename: Chen
authors.initials: C
authors.lastname: Chen
authors.forename: Liang
authors.initials: L
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D002296:Carcinosarcoma / Q000175:diagnosis / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000379:methods*; D008197:Lymph Node Excision; D008875:Middle Aged; D018200:Mixed Tumor, Mullerian / Q000175:diagnosis / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000601:surgery* / Q000628:therapy